BRISBANE - Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, announced that TRUTAKNA met all prespecified endpoints of the final efficacy analysis of the ORIGIN 3 trial in adults with primary IgA nephropathy (IgAN) at risk for disease progression.
These eGFR results align with the KDIGO treatment goal to reduce the rate of kidney function decline to the physiologic rate (
(C) 2026 Electronic News Publishing, source ENP Newswire